Cargando…
Successful Control of Hepatitis B Virus Reactivation following Restart of Ibrutinib in Chronic Lymphocytic Leukaemia
Ibrutinib is a targeted therapy drug that blocks the activity of Bruton's tyrosine kinase, and it is an approved treatment for several mature B-cell malignancies including chronic lymphocytic leukaemia (CLL). Side effects include infections, cytopenia, nausea, and diarrhoea. In this report, we...
Autores principales: | Tjønnfjord, Sara Kristina Viberg, Tjønnfjord, Eirik Brekka, Konopski, Zbigniew, Tjønnfjord, Geir Erland |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8553503/ https://www.ncbi.nlm.nih.gov/pubmed/34721911 http://dx.doi.org/10.1155/2021/1862446 |
Ejemplares similares
-
National trends in incidence and survival of chronic lymphocytic leukemia in Norway for 1953–2012: a systematic analysis of population‐based data
por: Lenartova, Andrea, et al.
Publicado: (2016) -
Cytokinesis arrest and multiple centrosomes in B cell chronic lymphocytic leukaemia
por: Rogne, Marie, et al.
Publicado: (2018) -
PB2608: THE MANAGEMENT OF IMMUNE THROMBOCYTOPENIA (ITP) IN NORWAY IN THE REAL LIFE – ANALYSIS OF THE NOR-ITP REGISTRY
por: Ilicheva, Ekaterina, et al.
Publicado: (2023) -
Determining drug dose in the era of targeted therapies: playing it (un)safe?
por: Skånland, Sigrid S., et al.
Publicado: (2022) -
Factor eight inhibitor bypass activity (FEIBA) in the management of bleeds in hemophilia patients with high-titer inhibitors
por: Tjønnfjord, Geir E, et al.
Publicado: (2007)